Cell signaling and cancer-possible targets for therapy

Journal of Cellular Physiology

Volumn 223, Issue 2, 2010, Pages 299-308

  Wenner, Charles E ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ION; CARDIAC GLYCOSIDE; GROWTH FACTOR; HEXOKINASE; PHOSPHATE TRANSPORTER; PROTEIN KINASE B; PROTEIN P53; REACTIVE OXYGEN METABOLITE; VOLTAGE DEPENDENT ANION CHANNEL 1;

APOPTOSIS; CANCER GROWTH; CANCER INHIBITION; CANCER RESEARCH; CARCINOGENESIS; CELL PROLIFERATION; CHANNEL GATING; DRUG RESEARCH; ENDOPLASMIC RETICULUM; ENERGY METABOLISM; ENZYME INDUCTION; GLYCOLYSIS; HUMAN; MITOCHONDRIAL RESPIRATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS REGULATORY PROTEINS; CELL TRANSFORMATION, NEOPLASTIC; DRUG DESIGN; GLYCOLYSIS; GROWTH INHIBITORS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; NEOPLASMS;

EID: 77950839507     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.22021     Document Type: Review

References (84)

1. Abu-Hamad S, Zaid H, Israelson A, Nahon E, Shoshan-Barmatz V. 2008. Hexokinase-I protection against apoptotic cell death is mediated via interaction with the voltagedependent anion channel-1: Mapping the site of binding. J Biol Chem 283:13482-13490.
2. Ahmad IM, Abdalla MY, Aykin-Burns N, Simons AL, OberleyLW, DomannFE, Spitz DR. 2008. 2-Deoxyglucose combined with wild-type p53 overexpression enhances cytotoxicity in human prostate cancer cells via oxidative stress. Free Radical Biology and Medicine 44:826-834.
3. 2 mediate glucose deprivation-induced stress in human cancer cells. J Biol Chem 280:4254-4263.
4. Arzoine L, Zilberberg N, Ben-Romano R, Shoshan-Barmatz V. 2009. Voltage-dependent anion channel 1-based peptides interact with hexokinase to prevent its antiapoptotic activity. J Biol Chem 284:3946-3955.
5. Azoulay-Zohar H, Israelson A, Abu-Hamad S, Shoshan-Barmatz V. 2004. In selfdefence: Hexokinase promotes voltage-dependent anion channel closure and prevents mitochondria-mediated apoptotic cell death. Biochem J 377:347-355.
6. Baines C. 2009a. The mitochondrial permeability transition pore and ischemia-reperfusion injury. Basic Res Cardiol 104:181-188.
7. Baines CP. 2007. The mitochondrial permeability transition pore as a target of cardioprotective signaling. Am J Physiol Heart Circ Physiol 293:H903-904.
8. Baines CP. 2009b. The molecular composition of the mitochondrial permeability transition pore. J Mol Cell Cardiol 46:850-857.
9. Balaban RS. 2009. Domestication of the cardiac mitochondrion for energy conversion. J Mol Cell Cardiol 46:832-841.
10. Bauer DE, Harris MH, Plas DR, Lum JJ, Hammerman PS, Rathmell JC, Riley JL, Thompson CB. 2004. Cytokine stimulation of aerobic glycolysis in hematopoietic cells exceeds proliferative demand. FASEB J 18:03-1001fje.
11. Baumgartner HK, Gerasimenko JV, Thorne C, Ferdek P, Pozzan T, Tepikin AV, Petersen OH, Sutton R,Watson AJM, Gerasimenko OV. 2009. Calcium elevation in mitochondria is the main Ca2+ requirement for mitochondrial permeability transition pore (mPTP) opening. J Biol Chem 284:20796-20803.
12. Bhaskar PT, Nogueira V, Patra KC, Jeon S-M, Park Y, Robey RB, Hay N. 2009. mTORC1 Hyperactivity Inhibits Serum Deprivation-Induced Apoptosis via Increased Hexokinase II and GLUT1 Expression, Sustained Mcl-1 Expression, and Glycogen Synthase Kinase 3β Inhibition. Mol Cell Biol 29:5136-5147.
13. Brand K. 1997. Aerobic glycolysis by proliferating cells: Protection against oxidative stress at the expense of energy yield. J Bioenerg Biomembr 29:355-364.
14. Colombini M. 2009. The published 3D structure of the VDAC channel: Native or not? Trends Biochem Sci 34:382-389.
15. Crompton M, Virji S, Ward JM. 1998. Cyclophilin-D binds strongly to complexes of the voltage-dependent anion channel and the adenine nucleotide translocase to form the permeability transition pore. Eur J Biochem 258:729-735.
16. Demaurex N, Poburko D, Frieden M. 2009. Regulation of plasma membrane calcium fluxes by mitochondria. Biochim Biophys Acta 1787:1383-1394.
17. Deniaud A, Sharaf el dein O, Maillier E, Poncet D, Kroemer G, Lemaire C, Brenner C. 2007. Endoplasmic reticulum stress induces calcium-dependent permeability transition, mitochondrial outer membrane permeabilization and apoptosis. Oncogene 27: 285-299.
18. Downward J. 2009. Cell biology: Metabolism meets death. Nature 424:896-897.
19. Edinger A, Thompson CB. 2004. Death by design: Apoptosis, necrosis and autophagy. Curr Opin Cell Biol 16:663-669.
20. Elstrom RL, Bauer DE, Buzzai M, Karnauskas R, Harris MH, Plas DR, Zhuang H, Cinalli RM, Alavi A, Rudin CM, Thompson CB. 2004. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res 64:3892-3899.
21. Gatenby RA, Gillies RJ. 2004a. Glycolysis in cancer: A potential target for therapy. Int J Biochem Cell Biol 39:1358-1366.
22. Gatenby RA, Gillies RJ. 2004b. Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4:891-899.
23. Gillies RJ, Robey I, Gatenby RA. 2008. Causes and consequences of increased glucose metabolism of cancers. J Nucl Med 49:24S-42S.
24. Gimenez-Cassina A, Lim F, Cerrato T, Palomo GM, Diaz-Nido J. 2009. Mitochondrial hexokinase II promotes neuronal survival and acts downstream of glycogen synthase kinase-3. J Biol Chem 284:3001-3011.
25. Gingras AC, Kennedy SG, O'Leary MA, Sonenberg N, Hay N. 1998. 4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway. Genes Dev 12:502-513.
26. Giorgi C, De Stefani D, Bononi A, Rizzuto R, Pinton P. 2009. Structural and functional link between the mitochondrial network and the endoplasmic reticulum. Int J Bio Cell Bio 41:1817-1827.
27. Gottlob K, Majewski N, Kennedy S, Kandel E, Robey RB, Hay N. 2001. Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase. Genes Dev 15:1406-1418.
28. Hadassah S, Nagamani SK, Mathew MK, Apurva S. 2004. The mitochondrial phase of the glucocorticoid-induced apoptotic response in thymocytes comprises sequential activation of adenine nucleotide transporter (ANT)-independent and ANTdependent events. Eur J Immunol 34:119-125.
29. Hahn-Windgassen A, Nogueira V, Chen C-C, Skeen JE, Sonenberg N, Hay N. 2005. Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity. J Biol Chem 280:32081-32089.
30. Halestrap AP, Pasdois P. 2009. The role of the mitochondrial permeability transition pore in heart disease. Biochim Biophys Acta 1787:1402-1415.
31. Hay N, Sonenberg N. 2004. Upstream and downstream of mTOR. Genes Dev 18:1926-1945.
32. Heath-Engel HM, Chang NC, Shore GC. 2008. The endoplasmic reticulum in apoptosis and autophagy: Role of the BCL-2 protein family. Oncogene 27:6419-6433.
33. Hines R, Wenner CE. 1977. The role of P(i) in glycolytic inhibition of calcium ion uptake by ELD ascites tumor cells. Biochim Biophys Acta 465:391-399.
34. Kandel ES, Hay N. 1999. The Regulation and Activities of the Multifunctional Serine/Threonine Kinase Akt/PKB. Exp Cell Res 253:210-229.
35. Kim J-W, Dang CV. 2005. Multifaceted roles of glycolytic enzymes. Trends Biochem Sci 30:142-150.
36. Klein S, McCormick F, Levitzki A. 2005. Killing time for cancer cells. Nat Rev Cancer 5:573-580.
37. Kroemer G, Pouyssegur J. 2008. Tumor Cell Metabolism: Cancer's Achilles' Heel. Cancer Cell 13:472-482. (Pubitemid 351766797)
38. Kumar S, BryantC, Chamala S, Qazi A, Seward S, Pal J, SteffesC, Weaver D, Morris R, Malone J, Shammas M, Prasad M, Batchu R. 2009. Ritonavir blocks AKT signaling, activates apoptosis and inhibits migration and invasion in ovarian cancer cells. Mol Cancer 8:26.
39. Lee MG, Pedersen PL. 2003. Glucose metabolism in cancer. J Biol Chem 278:41047-41058.
40. Lee AWM, States DJ. 2006. Colony-stimulating factor-1 requires PI3-kinase-mediated metabolism for proliferation and survival in myeloid cells. Cell Death Diff 13:1900-1914.
41. Lemasters JJ, Holmuhamedov E. 2006. Voltage-dependent anion channel (VDAC) as mitochondrial governator - Thinking outside the box. Biochim Biophys Acta 1762:181-190. (Pubitemid 43006024)
42. Leung AWC, Varanyuwatana P, Halestrap AP. 2008. The mitochondrial phosphate carrier interacts with cyclophilin D and may play a key role in the permeability transition. J Biol Chem 283:26312-26323.
43. Liguri G, Taddei N, Nassi P, Latorraca S, Nediani C, Sorbi S. 1990. Changes in Na+,K+- ATPase, Ca2+-ATPase and some soluble enzymes related to energy metabolism in brains of patients with Alzheimer's disease. Neurosci Lett 112:338-342.
44. Luo J, Emanuele MJ, LiD, Creighton CJ, Schlabach MR, Westbrook TF, Wong K-K, Elledge SJ. 2009. A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene. Cell 137:835-848.
45. Majewski N, Nogueira V, Robey RB, HayN. 2004. Akt inhibits apoptosis downstream of BID cleavage via a glucose-dependent mechanism involving mitochondrial hexokinases. Mol Cell Biol 24:730-740.
46. Mankoff DA, Eary JF, Link JM, Muzi M, Rajendran JG, Spence AM, Krohn KA. 2007. Tumor-specific positron emission tomography imaging in patients: [18F] Fluorodeoxyglucose and beyond. Clin Cancer Res 13:3460-3469. (Pubitemid 46955105)
47. Miyamoto S, Murphy AN, Brown JH. 2007. Akt mediates mitochondrial protection in cardiomyocytes through phosphorylation of mitochondrial hexokinase-II. Cell Death Differ 15:521-529. (Pubitemid 351267303)
48. Miyauchi H, Minamino T, Tateno K, Kunieda T, Toko H, Komuro I. 2004. Akt negatively regulates the in vitro lifespan of human endothelial cells via a p53/p21- dependent pathway. EMBO J 23:212-220. (Pubitemid 38165761)
49. Nemec KN, Khaled AR. 2008. Therapeutic modulation of apoptosis: Targeting the BCL-2 family at the interface of the mitochondrial membrane. Yonsei Med J 49:689-697.
50. Newman RA, Yang P, Pawlus AD, Block KI. 2008. Cardiac glycosides as novel cancer therapeutic agents. Mol Interv 8:36-49. (Pubitemid 351398451)
51. Nogueira V, Park Y, Chen CC, Xu PZ, Chen ML, Tonic I, Unterman T, Hay N. 2009. Akt determines replicative senescence and oxidative or oncogenic premature senescence and sensitizes cells to oxidative apoptosis. Cancer Cell 14:458-470.
52. Pastorino JG, Hoek JB, Shulga N. 2005. Activation of Glycogen Synthase Kinase 3β Disrupts the Binding of Hexokinase II to Mitochondria by Phosphorylating Voltage-Dependent Anion Channel and Potentiates Chemotherapy-Induced Cytotoxicity. Cancer Res 65:10545-10554. (Pubitemid 41743749)
53. Pastorino JG, Shulga N, Hoek JB. 2002. Mitochondrial Binding of Hexokinase II Inhibits Bax-induced Cytochrome c Release and Apoptosis. J Biol Chem 277:7610-7618. (Pubitemid 34953160)
54. Pastorino J, Hoek J. 2008. Regulation of hexokinase binding to VDAC. J Bioenerg Biomembr 40:171-182.
55. Pedersen P. 2007. Warburg, me and Hexokinase 2: Multiple discoveries of key molecular events underlying one of cancers' most common phenotypes, the "Warburg Effect", i.e., elevated glycolysis in the presence of oxygen. J Bioenerg Biomembr 39:211-222.
56. Pouyssegur J, Dayan F, Mazure NM. 2006. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 441:437-443. (Pubitemid 44050138)
57. Prassas I, Diamandis EP. 2008. Novel therapeutic applications of cardiac glycosides. Nat Rev Drug Discov 7:926-935.
58. Ramanathan A, Wang C, Schreiber SL. 2005. Perturbational profiling of a cell-line model of tumorigenesis by usingmetabolicmeasurements. ProcNatl Acad SciUSA 102:5992-5997. (Pubitemid 40594243)
59. Rathmell JC, Fox CJ, Plas DR, Hammerman PS,Cinalli RM, Thompson CB. 2003. Akt-directed glucose metabolism can prevent Bax conformation change and promote growth factorindependent survival. Mol Cell Biol 23:7315-7328.
60. Rizzuto R, Marchi S, BonoraM, Aguiari P, Bononi A, De Stefani D, Giorgi C, Leo S, Rimessi A, Siviero R, Zecchini E, Pinton P. 2009. Ca2+ transfer from the ER to mitochondria: When, how and why. Biochim Biophys Acta 1787:1342-1351.
61. Rizzuto R, Pozzan T. 2006. Microdomains of intracellular Ca2+: Molecular determinants and functional consequences. Physiol Rev 86:369-408.
62. Robey RB, Hay N. 2005. Akt, hexokinase, mTOR: Targeting cellular energy metabolism for cancer therapy. Drug Discov Today 2:239-246.
63. Robey RB, Hay N. 2006. Mitochondrial hexokinases, novel mediators of the antiapoptotic effects of growth factors and Akt. Oncogene 25:4683-4696. (Pubitemid 44187618)
64. Robey RB, Hay N. 2009. Is Akt the "Warburg kinase"?-Akt-energy metabolism interactions and oncogenesis. Semin Cancer Biol 19:25-31.
65. Rong Y, Distelhorst CW.2008. Bcl-2 protein family members: Versatile regulators of calcium signaling in cell survival and apoptosis. Ann Rev Physiol 70:73-91. (Pubitemid 351738172)
66. Scholl C, Fröhling S, Dunn IF, Schinzel AC, Barbie DA, Kim SY, Silver SJ, Tamayo P, Wadlow RC, Ramaswamy S,Döhner K, Bullinger L, Sandy P, Boehm JS, Root DE, Jacks T, Hahn WC, Gilliland DG. 2009. Synthetic Lethal Interaction between Oncogenic KRAS Dependency and STK33 Suppression in Human Cancer Cells. Cell 137:821-834.
67. Scorrano L. 2003. Divide et impera: Ca2+ signals, mitochondrial fission and sensitization to apoptosis. Cell Death Differ 10:1287-1289. (Pubitemid 37536733)
68. Semenza G. 2007. HIF-1 mediates theWarburg effect in clear cell renal carcinoma. J Bioenerg Biomembr 39:231-234. (Pubitemid 47619375)
69. Shoshan-Barmatz V, Zakar M, Rosenthal K, Abu-Hamad S. 2009. Key regions of VDAC1 functioning in apoptosis induction and regulation by hexokinase. Biochim Biophys Acta 1787:421-430.
70. Szabadkai G, Duchen M. 2009. Mitochondria mediated cell death in diabetes. Apoptosis 14:1405-1423.
71. Thompson JE, Thompson CB. 2004. Putting the Rap on Akt. J Clin Oncol 22:4217-4226.
72. Tomasello F, Messina A, Lartigue L, Schembri L, Medina C, Reina S, Thoraval D, Crouzet M, Ichas F, De Pinto V, De Giorgi F. 2009. Outer membrane VDAC1 controls permeability transition of the inner mitochondrial membrane in cellular during stress-induced apoptosis. Cell Res 19:1363-1376.
73. Ujwal R, Cascio D, Colletier J-P, Faham S, Zhang J, Toro L, Ping P, Abramson J. 2008. The crystal structure of mouse VDAC1 at 2.3 Ã resolution reveals mechanistic insights into metabolite gating. Proc Natl Acad Sci 105:17742-17747.
74. Vander Heiden MG, Cantley LC, Thompson CB. 2009. Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science 324:1029-1033.
75. Veenman L, Shandalov Y, Gavish M. 2008. VDAC activation by the 18 kDa translocator protein (TSPO), implications for apoptosis. J Bioenerg Biomembr 40:199-205.
76. Verrax J, Pedrosa RC, Beck R, Dejeans N, Taper H, Calderon PBuc. 2009. In situ modulation of oxidative stress: A novel and efficient strategy to kill cancer cells. Curr Med Chem 16:1821-1830.
77. Weber WA. 2007. 18F-FDG PET in non-Hodgkin's lymphoma: Qualitative or quantitative? J Nucl Med 48:1580-1582.
78. Weinhouse S. 1976. The Warburg hypothesis fifty years later. J Cancer Rec Clin Oncol 87:115-126.
79. Xie Z,Cai T. 2003. Na+-K+-ATPase-mediated signal transduction: From protein interaction to cellular function. Mol Interv 3:157-168.
80. Yuan S, Fu Y,Wang X, Shi H, Huang Y, Song X, Li L, Song N, Luo Y. 2008. Voltage-dependent anion channel 1 is involved in endostatin-induced endothelial cell apoptosis. FASEB J 22:2809-2820.
81. Yun J, Rago C, Cheong I, Pagliarini R, Angenendt P, Rajagopalan H, Schmidt K, Willson JKV, Markowitz S, Zhou S, Diaz LA Jr, Velculescu VE, Lengauer C, Kinzler KW, Vogelstein B, Papadopoulos N. 2009. Glucose Deprivation Contributes to the Development of KRAS Pathway Mutations in Tumor Cells. Science 325:1555-1559.
82. Zhang H, Qian DZ, Tan YS, Lee K, Gao P, Ren YR, Rey S, Hammers H, Chang D, Pili R, Dang CV, Liu JO, Semenza GL. 2008. Digoxin and other cardiac glycosides inhibit HIF-1a synthesis and block tumor growth. Proc Natl Acad Sci 105:19579-19586.
83. Zhao X,Wang L, Sun Y, Ye L, Lu J, Yuan Y, Qian G, Ge S. 2008. The endoplasmic reticulum (ER)-target protein Bik induces Hep3B cells apoptosis by the depletion of the ER Ca2+ stores. Mol Cell Biochem 312:33-38.
84. Zheng Y, Shi Y, Tian C, JiangC, Jin H, Chen J, Almasan A, Tang H, Chen Q. 2003. Essential role of the voltage-dependent anion channel (VDAC) in mitochondrial permeability transition pore opening and cytochrome c release induced by arsenic trioxide. Oncogene 23:1239-1247. (Pubitemid 38297178)